|
Joinn LaboratoriesCo.,Ltd. (6127.HK) DCF Valuation
CN | Healthcare | Medical - Diagnostics & Research | HKSE
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Joinn Laboratories(China)Co.,Ltd. (6127.HK) Bundle
Explore Joinn Laboratories (China) Co., Ltd. (6127HK) financial future with our easy-to-use DCF Calculator! Enter your assumptions for growth, margins, and costs to calculate Joinn Laboratories (China) Co., Ltd. (6127HK) intrinsic value and enhance your investment strategy.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 682.8 | 1,148.9 | 1,619.6 | 2,421.9 | 2,537.7 | 3,575.4 | 5,037.4 | 7,097.2 | 9,999.3 | 14,088.1 |
| Revenue Growth, % | 0 | 68.27 | 40.97 | 49.54 | 4.78 | 40.89 | 40.89 | 40.89 | 40.89 | 40.89 |
| EBITDA | 275.4 | 450.7 | 761.3 | 1,453.7 | 682.9 | 1,526.7 | 2,151.0 | 3,030.5 | 4,269.7 | 6,015.6 |
| EBITDA, % | 40.33 | 39.23 | 47.01 | 60.02 | 26.91 | 42.7 | 42.7 | 42.7 | 42.7 | 42.7 |
| Depreciation | 45.2 | 64.8 | 103.0 | 129.2 | 138.3 | 210.3 | 296.2 | 417.4 | 588.1 | 828.5 |
| Depreciation, % | 6.63 | 5.64 | 6.36 | 5.33 | 5.45 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 |
| EBIT | 230.1 | 385.9 | 658.3 | 1,324.5 | 544.6 | 1,316.4 | 1,854.7 | 2,613.1 | 3,681.7 | 5,187.1 |
| EBIT, % | 33.71 | 33.59 | 40.65 | 54.69 | 21.46 | 36.82 | 36.82 | 36.82 | 36.82 | 36.82 |
| Total Cash | 328.5 | 584.7 | 5,163.1 | 3,550.9 | 5,093.4 | 2,853.3 | 4,020.0 | 5,663.8 | 7,979.7 | 11,242.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 115.6 | 168.6 | 229.1 | 363.2 | 363.1 | 536.7 | 756.2 | 1,065.4 | 1,501.0 | 2,114.8 |
| Account Receivables, % | 16.94 | 14.67 | 14.14 | 15 | 14.31 | 15.01 | 15.01 | 15.01 | 15.01 | 15.01 |
| Inventories | 214.1 | 433.8 | 748.1 | 2,343.5 | 1,989.5 | 2,077.1 | 2,926.4 | 4,123.0 | 5,808.9 | 8,184.2 |
| Inventories, % | 31.36 | 37.76 | 46.19 | 96.77 | 78.4 | 58.09 | 58.09 | 58.09 | 58.09 | 58.09 |
| Accounts Payable | 46.7 | 64.4 | 57.3 | 135.9 | 46.3 | 167.4 | 235.9 | 332.3 | 468.2 | 659.6 |
| Accounts Payable, % | 6.83 | 5.6 | 3.54 | 5.61 | 1.82 | 4.68 | 4.68 | 4.68 | 4.68 | 4.68 |
| Capital Expenditure | -135.4 | -159.1 | -253.3 | -293.5 | -205.8 | -497.3 | -700.7 | -987.2 | -1,390.8 | -1,959.5 |
| Capital Expenditure, % | -19.83 | -13.85 | -15.64 | -12.12 | -8.11 | -13.91 | -13.91 | -13.91 | -13.91 | -13.91 |
| Tax Rate, % | 21.69 | 21.69 | 21.69 | 21.69 | 21.69 | 21.69 | 21.69 | 21.69 | 21.69 | 21.69 |
| EBITAT | 199.4 | 337.2 | 571.6 | 1,147.5 | 426.5 | 1,121.0 | 1,579.4 | 2,225.2 | 3,135.1 | 4,417.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -173.8 | -12.1 | 39.3 | -667.7 | 623.4 | 694.0 | 174.7 | 246.1 | 346.7 | 488.5 |
| WACC, % | 7.82 | 7.82 | 7.82 | 7.82 | 7.82 | 7.82 | 7.82 | 7.82 | 7.82 | 7.82 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,581.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 498 | |||||||||
| Terminal Value | 8,559 | |||||||||
| Present Terminal Value | 5,873 | |||||||||
| Enterprise Value | 7,455 | |||||||||
| Net Debt | -3,012 | |||||||||
| Equity Value | 10,468 | |||||||||
| Diluted Shares Outstanding, MM | 749 | |||||||||
| Equity Value Per Share | 13.97 |
What You Will Receive
- Authentic JOINN Financial Data: Comes pre-loaded with JOINN Laboratories’ historical and projected figures for accurate analysis.
- Fully Customizable Template: Easily adjust key parameters such as revenue growth, WACC, and EBITDA %.
- Real-Time Calculations: Instantly view updates to JOINN’s intrinsic value as you make changes.
- Professional Valuation Tool: Tailored for investors, analysts, and consultants in pursuit of precise DCF outcomes.
- User-Friendly Layout: Straightforward design and clear guidance suitable for any level of expertise.
Key Features
- Accurate Financial Data: Gain access to reliable historical figures and future forecasts for Joinn Laboratories (China) Co., Ltd. (6127HK).
- Tailored Forecast Assumptions: Customize editable highlighted cells to modify WACC, growth rates, and profit margins to suit your analysis.
- Real-Time Calculations: Benefit from automatic updates to DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: View easy-to-interpret charts and summaries that present your valuation outcomes clearly.
- Designed for All Skill Levels: An intuitive layout catering to investors, CFOs, and consultants alike, suitable for both experts and novices.
How It Works
- Step 1: Download the prebuilt Excel template containing Joinn Laboratories(China)Co.,Ltd. (6127HK) data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Adjust forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: View updated results immediately, including Joinn Laboratories(China)Co.,Ltd.'s (6127HK) intrinsic value.
- Step 5: Use the outputs to make informed investment decisions or create comprehensive reports.
Why Opt for This Calculator?
- Designed for Experts: A sophisticated tool tailored for analysts, CFOs, and consultants.
- Accurate Financial Data: Joinn Laboratories (China) Co., Ltd.’s historical and projected financials are preloaded for reliability.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance makes the process straightforward.
Who Can Benefit from This Product?
- Institutional Investors: Create comprehensive and dependable valuation models for investment assessments of Joinn Laboratories (6127HK).
- Finance Teams: Evaluate various valuation scenarios to inform strategic decisions within the company.
- Financial Consultants: Equip clients with precise valuation analyses for Joinn Laboratories (6127HK).
- Academic Professionals and Students: Utilize actual market data to enhance financial modeling skills and education.
- Industry Enthusiasts: Gain insight into the valuation processes of biotechnology firms like Joinn Laboratories (6127HK).
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Joinn Laboratories (China) Co., Ltd. (6127HK), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for the Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models that provide intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios relevant to Joinn Laboratories (China) Co., Ltd. (6127HK).
- Dashboard and Charts: Visual representation of valuation outputs and assumptions for easy analysis of results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.